Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
38 authors.
James R W ConwayGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-3787-277X
Sean C WarrenGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-5253-7147
Young-Kyung LeeGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-0212-0164
Andrew T McCullochGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.
Astrid MagenauGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.
Victoria LeeGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-0701-8321
Xanthe L MetcalfGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0001-9599-9280
Janett StoehrGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-4198-3520
Katharina HaighDepartment of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Lea AbdulkhalekGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.
Cristian S GuamanGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-2676-2575
Daniel A ReedGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-3736-7725
Kendelle J MurphyGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-3234-3812
Brooke A PereiraGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-3513-1214
Pauline MélénecGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0001-6486-2003
Cecilia ChambersGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-4979-9349
Sharissa L LathamGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-1128-5315
Helen LenthallGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.
Elissa K DeenickGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-9271-0004
Yuanqing MaGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-0557-4559
Tri PhanGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-4909-2984
Elgene LimGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0001-8065-8838
Anthony M JoshuaGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0001-5159-4580
Stacey WaltersGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0001-5937-2341
Shane T GreyGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-2160-1625
Yan-Chuan ShiGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-8368-6735
Lei ZhangGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-3927-8881
Herbert HerzogGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.
David R CroucherGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0003-4965-8674
Andy PhilpSchool of Clinical Medicine, Randwick Clinical Campus, UNSW Sydney, Centre for Healthy Ageing, Centenary Institute, Missenden Road, Sydney, NSW 2050, Australia.
Colinda L G J ScheeleLaboratory for Intravital Imaging and Dynamics of Tumor Progression, VIB Center for Cancer Biology, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-8999-5451
David HerrmannGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-9514-7501
Antonella PapaMonash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0001-8653-7121
Jody J HaighDepartment of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-7319-8922
Max NobisGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-1861-1390
Paul TimpsonGarvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia.ORCID 0000-0002-5514-7080
Funding
Cancer Research UK 29996
6 · The paper itself
Abstract
Aberrant AKT activation occurs in a number of cancers, metabolic syndrome, and immune disorders, making it an important target for the treatment of many diseases. To monitor spatial and temporal AKT activity in a live setting, we generated an Akt-FRET biosensor mouse that allows longitudinal assessment of AKT activity using intravital imaging in conjunction with image stabilization and optical window technology. We demonstrate the sensitivity of the Akt-FRET biosensor mouse using various cancer models and verify its suitability to monitor response to drug targeting in spheroid and organotypic models. We also show that the dynamics of AKT activation can be monitored in real time in diverse tissues, including in individual islets of the pancreas, in the brown and white adipose tissue, and in the skeletal muscle. Thus, the Akt-FRET biosensor mouse provides an important tool to study AKT dynamics in live tissue contexts and has broad preclinical applications.
Indexed as
Biosensing TechniquesProto-Oncogene Proteins c-aktAnimalsFluorescence Resonance Energy TransferMiceProto-Oncogene Proteins c-akt
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.